Takeda Acquires Adaptate Biotherapeutics

Takeda Acquires GammaDelta Therapeutics

October 27, 2021

Biotechnology

Takeda Pharmaceutical Company Limited has exercised its option to acquire GammaDelta Therapeutics Limited, obtaining the company's allogeneic Vδ1 γδ T cell therapy platforms and early-stage cell therapy programs. The acquisition, stemming from a multi-year collaboration begun in 2017, is for a pre-negotiated upfront payment plus potential milestone payments and is expected to close in Q1 of Takeda's fiscal 2022, subject to antitrust review.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

Takeda Pharmaceutical Company Limited Acquires Maverick Therapeutics, Inc.

March 9, 2021

Biotechnology

Takeda exercised its option to acquire Maverick Therapeutics, obtaining Maverick's COBRA conditionally active bispecific T‑cell engager platform and lead development candidates (TAK‑186 and TAK‑280). The deal, based on a prior collaboration and equity stake, is structured for up to $525 million in upfront and potential milestone payments and will fold Maverick's R&D team into Takeda's organization.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.

Genmab Acquires ProfoundBio for $1.8 Billion

April 3, 2024

Biotechnology

Genmab A/S will acquire clinical-stage biotech ProfoundBio, Inc. in an all-cash transaction valued at USD 1.8 billion to obtain worldwide rights to ProfoundBio's pipeline of antibody-drug conjugates (ADCs), including rinatabart sesutecan (Rina-S). The deal is intended to broaden and strengthen Genmab's oncology and ADC capabilities and is expected to close in the first half of 2024, subject to customary conditions.

BiomX Acquires Adaptive Phage Therapeutics

March 18, 2024

Biotechnology

BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.